3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lung Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
6
Sarcoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Thymoma
2
Rectal Neoplasms
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Leukemia, Myelomonocytic, Chronic
2
Esophageal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
24
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
Celecoxib
×
Clear all
NCT02115074
2026-03-18
FLUVABREX
Centre Oscar Lambret
Phase 1
Completed
20 enrolled